ReviewBone marrow transplantation2008
Role of HLA in hematopoietic SCT.
Review in Bone marrow transplantation, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 60 citations in OpenAlex.
- Superior outcomes with offspring B-leader-matched haploidentical versus older matched sibling donors in AL/MDS patients aged ≥40 years.Frontiers in immunology · 2026Article
- Quantifying HLA transcripts by genotype in chimeric mixtures at single-cell resolution.bioRxiv : the preprint server for biology · 2025Article
- Long-term endocrine sequelae after hematopoietic stem cell transplantation in children and adolescents.Annals of pediatric endocrinology & metabolism · 2024Article
- Graph-Based Imputation Methods and Their Applications to Single Donors and Families.Methods in molecular biology (Clifton, N.J.) · 2024Article
- Relapse of acute myeloid leukemia after allogeneic stem cell transplantation: immune escape mechanisms and current implications for therapy.Molecular cancer · 2023Review
- Modeling glioblastoma complexity with organoids for personalized treatments.Trends in molecular medicine · 2023Review
- Activity of daily living in mucopolysaccharidosis IVA patients: Evaluation of therapeutic efficacy.Molecular genetics & genomic medicine · 2021Article
- Differential Leukocyte MicroRNA Responses Following Pan T Cell, Allorecognition and Allosecretome-Based Therapeutic Activation.Archivum immunologiae et therapiae experimentalis · 2021Article
- Posttransplantation cyclophosphamide vs. antithymocyte globulin as GVHD prophylaxis for mismatched unrelated hematopoietic stem cell transplantation.Bone marrow transplantation · 2020Article
- Expansion of Haematopoietic Stem and Progenitor Cells: Paving the Way for Next-Generation Haematopoietic Stem Cell Transplantation.Blood cell therapy · 2019Review
- Protein dysregulation in graft versus host disease.Oncotarget · 2018Review
- Milestones of Hematopoietic Stem Cell Transplantation - From First Human Studies to Current Developments.Frontiers in immunology · 2016Review
- Allele frequency net 2015 update: new features for HLA epitopes, KIR and disease and HLA adverse drug reaction associations.Nucleic acids research · 2015Article
- The effect of the CCR5-delta32 deletion on global gene expression considering immune response and inflammation.Journal of inflammation (London, England) · 2011Article
- Shedding a new light on the HLA matching.The Korean journal of hematology · 2011Article
- Article
- Understanding population-wide haplotype frequencies of human leukocyte antigen (HLA) alleles in linkage disequilibrium is important for hematopoietic stem cell transplantation.Revista brasileira de hematologia e hemoterapiaArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
HLA disparity between hematopoietic stem cell (HSC) donor and recipient triggers T-cell and NK-cell allorecognition, and induces the GVHD, GVL effect and/or may cause an engraftment failure. This review will cover the scope of human genomic variation, the methods of HLA typing and interpretation of high-resolution HLA results. We describe the main subsets of related and unrelated HSC donors and outline the main aspects of HLA disparity and their effect on the outcome of the patients after allogeneic HSC transplantation (HSCT). The HLA match between HSCT donor and recipient is crucial, but for many patients a perfectly matched donor is not available. The HSCT from the alternative mismatched donor with one allele/antigen mismatch (9/10) can be as beneficial as a HSCT from a fully matched donor, especially in younger patients. For the remaining patients, the donors with permissive mismatches may be the option. The permissiveness depends not only on the potential adverse effect of the HLA mismatches, but also on the urgency of the transplantation, the desirable GVL effect and the potential efficacy of the alternative therapy available for the patient.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.